

ASX ANNOUNCEMENT

25 May 2023

Results of Extraordinary General Meeting

Melbourne, Australia; 25 May 2023: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), advises that its Extraordinary General Meeting of Shareholders was held today at 10.30 am AEST.

The resolutions were voted in accordance with the Notice of Extraordinary General Meeting previously advised to the Australian Securities Exchange, other than for Resolution 4 – Approval to Issue Shortfall Shares and attaching Options in connection with the Share Purchase Plan (SPP). Given that the Share Purchase Plan (SPP) was oversubscribed there was accordingly no shortfall under the SPP and thus Resolution 4 was withdrawn.

Resolutions 1 to 3 and 5 to 10 were passed on a poll.

Further information required by section 251AA(2) of the *Corporations Act 2001 (Cth)* is attached.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343, ross.macdonald@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, littlebigdealconsulting@gmail.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD under a cleared US FDA IND is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

Disclosure of Proxy Votes

Cynata Therapeutics Limited

General Meeting

Thursday, 25 May 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Ratification of issue of Shares under the Unconditional Placement	P	29,461,633	26,761,376 90.83%	1,238,760 4.20%	14,193,597	1,461,497 4.96%	28,277,873 95.80%	1,238,760 4.20%	14,193,597
2 Approval to issue Options under the Unconditional Placement	P	29,461,633	26,590,214 90.25%	1,409,922 4.79%	14,193,597	1,461,497 4.96%	28,106,711 95.22%	1,409,922 4.78%	14,193,597
3 Approval to issue Options to Shareholders in connection with the Share Purchase Plan	P	43,092,382	40,420,535 93.80%	1,210,350 2.81%	14,202,069	1,461,497 3.39%	41,886,337 97.19%	1,210,350 2.81%	14,202,069
4 Approval to issue Shortfall Shares and attaching Options in connection with the Share Purchase Plan	P	53,330,324	50,658,477 94.99%	1,210,350 2.27%	14,202,069	1,461,497 2.74%	52,174,974 97.73%	1,210,350 2.27%	14,202,069
5 Approval to issue Shares and Options to Dr Geoff Brooke under the Director Placement	P	67,457,596	64,906,196 96.22%	2,274,314 3.37%	74,797	277,086 0.41%	65,238,282 96.63%	2,274,314 3.37%	74,797
6 Approval to issue Shares and Options to Dr Ross Macdonald under the Director Placement	P	65,447,033	62,896,733 96.10%	2,273,214 3.47%	15,310	277,086 0.42%	63,228,819 96.53%	2,273,214 3.47%	15,310
7 Approval to issue Shares and Options to Dr Darryl Maher under the Director Placement	P	67,457,596	64,906,196 96.22%	2,274,314 3.37%	74,797	277,086 0.41%	65,238,282 96.63%	2,274,314 3.37%	74,797

			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 Approval to issue Shares and Options to Ms Janine Rolfe under the Director Placement	P	67,457,596	64,906,196 96.22%	2,274,314 3.37%	74,797	277,086 0.41%	65,238,282 96.63%	2,274,314 3.37%	74,797
9 Approval to issue Shares and Options to Dr Stewart Washer under the Director Placement	P	65,172,740	62,621,340 96.09%	2,274,314 3.49%	279,653	277,086 0.43%	62,953,426 96.51%	2,274,314 3.49%	279,653
10 Approval to issue Shares and Options to Dr Paul Wotton under the Director Placement	P	67,457,496	64,906,096 96.22%	2,274,314 3.37%	74,797	277,086 0.41%	65,238,182 96.63%	2,274,314 3.37%	74,797

